beta
Trial Radar IA
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca

Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists Fase II 24

Non ancora in arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT07221461 è uno studio interventistico di Fase II volto a esaminare il trattamento per Ruga, attualmente non ancora in arruolamento. L'arruolamento dovrebbe iniziare il 1 novembre 2025, con l'obiettivo di raggiungere 24 partecipanti. Sotto la guida di Goldman, Butterwick, Fitzpatrick and Groff, dovrebbe concludersi entro il 2 marzo 2026. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 28 ottobre 2025.
Sommario breve
Clinical trial to assess the effect of microdroplet hyaluronic acid filler to the cheek skin (SKINVIVE™, JUVÉDERM®, Irvine, CA) on skin quality in patients undergoing medical weight loss with GLP-1 therapy.
Descrizione dettagliata
24 patients total (16 GLP1 and 8 non-GLP1) will receive one treatment with microdroplet hyaluronic acid filler (SKINVIVE™, JUVÉDERM®, Irvine, CA) to the cheeks, either at the beginning of the study or at the end. Patients will return for follow up visits at day 30, day 60 and and day 70, where they will undergo standardized 2D photography, VISIA photography and assessments.
Titolo ufficiale

Prospective, Single Center, Open-label Study Assessing Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality and Biomarkers in Patients on Glucagon-like Peptide-1 Agonists

Patologie
Ruga
Altri ID dello studio
  • Skinvive GLP1 agonist
Numero NCT
NCT07221461
Data di inizio (effettiva)
2025-11-01
Ultimo aggiornamento pubblicato
2025-10-28
Data di completamento (stimata)
2026-03-02
Arruolamento (previsto)
24
Tipo di studio
Interventistico
FASE
Fase II
Stato
Non ancora in arruolamento
Parole chiave
skin laxity
fine lines
dull skin
uneven skin tone
Scopo principale
Trattamento
Allocazione
Non randomizzato
Modello di intervento
In parallelo
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Comparatore attivoGLP1 Patients
16 participants who have been on a stable dose of GLP-1 agonist medication for at least the last 6 months will receive one treatment with microdroplet hyaluronic acid filler (SKINVIVE™, JUVÉDERM®, Irvine, CA) to the cheeks.
Skinvive
16 GLP1 subjects treated with Skinvive to their cheeks for skin quality will be compared to 8 NON-GLP1 subjects treated with Skinvive for skin quality.
SperimentaleNON GLP1 Patients
8 participants who are GLP1 naive will receive one treatment with microdroplet hyaluronic acid filler (SKINVIVE™, JUVÉDERM®, Irvine, CA) to the cheeks.
Skinvive
16 GLP1 subjects treated with Skinvive to their cheeks for skin quality will be compared to 8 NON-GLP1 subjects treated with Skinvive for skin quality.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Global Fine Lines
Score 0 no fine lines thru 9 numerous, many fine lines
Screening, Day 30, Day 60
Overall Hyperpigmentation
Score 0= no hyperpigmentation thru 9= significant hyperpigmentation
Screening, Day 30, Day 60
Skin Tone Evenness
Score 0= Very even tone thru Score 9= Uneven, discolored appearance (brown and/or red colors)
Screening, Day 30, Day 60
Skin Firmness
Score 0= Firm, tight feeling skin thru Score 9= Loose, lax feeling skin
Screening, Day 30, Day 60
Skin Radiance/ Brightness
Score 0= Very radiant, luminous or glowing appearance thru Score 9= Very dull/ matte and/or sallow skin appearance
Screening, Day 30, Day 60
Skin Texture Smoothness
Score 0= Very smooth, even-looking skin texture, no roughness thru Score 9= Very rough, pronounced, extensive visible skin roughness
Screening, Day 30, Day 60
Global Wrinkles
Score 0= No wrinkles present, no visible deep, wide and long wrinkles, skin looks smooth thru Score 9= Numerous wrinkles, deep, wide and long, densely packed together in the treatment area
Screening, Day 30, Day 60
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
Physical Global Aesthetic Improvement Scale
Assess improvement of Abdominal skin laxity: Much Improved 2 Improved 1 No Change 0 Worse -1 Much Worse -2
Day 30 and Day 60
Subject Global Aesthetic Improvement Scale
Assess improvement of Abdominal skin laxity: Much Improved 2 Improved 1 No Change 0 Worse -1 Much Worse -2
Day 30 and Day 60
Assistente alla partecipazione
Criteri di eleggibilità

Età idonea
Adulto
Età minima
25 Years
Sessi idonei
Femmina
Accetta volontari sani
Sì

  1. Adult women aged 25-50 years.

  2. Fitzpatrick skin types I-VI.

  3. Current treatment with a stable dose of GLP-1 agonist medication for at least the last 6 months, for 16 of the enrolled subjects. Remaining 8 subjects should not be taking or have a history of taking a GLP-1 agonist therapy in the last year.

  4. Presence of moderate skin changes (as defined by Modified Griffiths' Scale, with an average score of 4-6) in the following criteria: skin radiance/brightness, skin elasticity, tone evenness, skin firmness, fine lines, global wrinkles, and skin smoothness (tactile and visual).

  5. Participants must maintain a stable weight, defined as no greater than a 10% weight change from screening/baseline and throughout the study.

  6. Participants must have a body mass index (BMI) of 27 or less.

  7. Must be willing to sign a photography release and ICF, and complete the entire course of the study.

  8. Participant must agree to maintaining the same skincare routine they are currently using throughout the study period.

  9. Subjects in good general health based on investigator's judgment and medical history.

  10. Negative urine pregnancy test result at the time of study entry (if applicable).

  11. Females of childbearing potential must be willing to use an acceptable method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.

    1. 1. Acceptable methods of birth control are: oral contraceptive pill, injections, implants, patches, vaginal rings, intrauterine device/coil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and/or vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.
    2. 2. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and/or both ovaries (oophorectomy), or bilateral tubal ligation.

  1. The presence of severe facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 7-9) or minimal facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 0-3).
  2. Females who are pregnant, planning a pregnancy, or currently breast feeding during the study.
  3. Any uncontrolled systemic disease.
  4. History of autoimmune connective tissue disease.
  5. Current use of immunosuppressive medication.
  6. Weight change of greater than 10% during the study period.
  7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
  8. Active dermatitis (including but not limited to atopic dermatitis, psoriasis, rosacea, acne, melasma, etc.), active infections, or other skin condition in the proposed treatment area that in the investigator's opinion might interfere with the evaluation of study parameters.
  9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment. Botulinum toxin injections (Botox, Dysport, Xeomin, Daxify, Jeuveau) during the 6-month period before study treatment.
  10. Any investigational treatment for skin quality of the cheeks during the 12-month period before the study treatment.
  11. Creams/cosmeceuticals and/or home therapies for the prevention or treatment of skin fine lines, wrinkles, radiance, elasticity, firmness, or smoothness in the treatment area during the 4-week period before study treatment and throughout the course of the study.
  12. Subjects with scarring in the treatment areas. Subjects with a history of keloids will be excluded.
  13. Subjects who spray tanned or used sunless tanners in the treatment areas 4 weeks prior to study treatment.
  14. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and/or current pregnancy or breastfeeding.
  15. Inability to ambulate following the procedure.
  16. History of lidocaine and/or tetracaine sensitivity deemed by the investigator to preclude subject from enrolling into study.
  17. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.
  18. Subjects planning any cosmetic procedure to the treatment area during the study period, other than the treatment that will be performed by the investigator.
  19. Use of topical steroids, retinoids/retinols, or vitamin C to the face within the previous 2-weeks of screening.
  20. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
Goldman, Butterwick, Fitzpatrick and Groff logoGoldman, Butterwick, Fitzpatrick and Groff
Contatti principali dello studio
Contatto: Andrea Pacheco, 858-657-1004, [email protected]
1 Centri dello studio in 1 paesi

California

West Dermatology Research Center, San Diego, California, 92121, United States
Andrea Pacheco, Contatto, 858-657-1004, [email protected]
Freia Canals-Cistero, Contatto, 858-657-1004, [email protected]